Keap1-Nrf2

Nrf2 activator-5 is a potent activator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. This compound effectively reduces hydrogen peroxide-induced oxidative stress and lipopolysaccharide (LPS)-induced inflammation in BV-2 microglial cells. Nrf2 activator-5 demonstrates significant antioxidant and anti-inflammatory properties, making it valuable for research into neuroinflammation and oxidative stress.

Keap1-Nrf2-IN-3 is a selective inhibitor targeting the KEAP1-NRF2 protein-protein interaction, demonstrating a Kd value of 2.5 nM for KEAP1. This compound enhances NRF2 activity, leading to elevated expression of antioxidant response genes. It is valuable for research applications focused on oxidative stress, cancer biology, and neuroprotection, providing insights into mechanisms influencing cellular defense pathways.

Keap1-Nrf2-IN-28 is a potent inhibitor of the Keap1-Nrf2 signaling pathway. This compound exhibits significant antioxidant activity by promoting the upregulation of Nrf2 and its downstream targets, including HO-1, GCLM, and Akr1c1. Additionally, Keap1-Nrf2-IN-28 has been shown to mitigate acute liver injury induced by acetaminophen, making it a valuable tool in research related to oxidative stress and liver protection.

Fraxinellone analog 1 is a potent Nrf2 activator that enhances the antioxidant defense system and protects against glutamate-mediated excitotoxicity. This compound induces the expression of key antioxidant genes, including Gpx4, Sod1, and Nqo1, demonstrating neuroprotective effects and regulatory capabilities against oxidative stress and inflammation. Fraxinellone analog 1 is valuable for research applications focused on neurodegenerative diseases and related oxidative stress models.

Keap1-Nrf2-IN-5 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction (PPI), with an IC50 of 4.1 µM and a Kd of 3.7 µM. This compound enhances Nrf2 activity, promoting the expression of antioxidant and cytoprotective genes. It serves as a valuable tool for research into oxidative stress, neuroprotection, and cancer therapeutics.

Nrf2 activator 17 is a potent activator of the Nrf2 signaling pathway, functioning by inhibiting the interaction between Keap1 and Nrf2 with an IC50 of less than 0.1 pM. This compound demonstrates significant biological activity, exhibiting an EC50 of less than 10 µM in HepG2 cells. Nrf2 activator 17 is utilized in research applications focused on oxidative stress, cellular protection, and the study of Nrf2-related pathways in various disease models.

Nrf2 activator-20 is a potent Nrf2 activator that enhances anti-inflammatory and antioxidant responses by disrupting the Keap1-Nrf2 interaction. It has demonstrated beneficial effects in vivo, making it suitable for research applications involving acute respiratory distress syndrome (ARDS) and ischemia-reperfusion injury. This reagent serves as a valuable tool for studying the modulation of oxidative stress and inflammation pathways in various biological contexts.

R079 is a selective, orally active Nrf2 activator that enhances Nrf2 translocation with an EC50 of 32.41 μM. By activating Nrf2, R079 effectively neutralizes excess reactive oxygen species, contributing to its anti-inflammatory properties. This compound serves as a valuable tool for research into oxidative stress and inflammatory conditions, including multiple sclerosis.

Keap1-Nrf2 Probe is designed to selectively bind to the Kelch-like ECH-associated protein 1 (Keap1), modulating the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway. By inhibiting Keap1 function, this probe enhances the transcription of antioxidant response elements, promoting cellular defense against oxidative stress. It is valuable for research on oxidative stress-related diseases, drug discovery targeting the Nrf2 pathway, and studying cellular mechanisms involved in stress responses.

Rosolic acid is a potent activator of Nrf2, leading to the upregulation of its downstream targets. This compound has been shown to enhance levels of angiogenic factors while reducing inflammation markers such as TNF-α and IL-1β, as well as apoptotic markers like CXCL10 and CCL2. Additionally, rosolic acid aids in restoring pancreatic cell function and offers protective effects on endothelial cells against endoplasmic reticulum stress. Its applications include studies on oxidative stress, inflammation modulation, and cellular protection mechanisms.

Keap1-Nrf2-IN-8 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, demonstrating IC50 values of 64.5 nM and 14.2 nM in fluorescence polarization and time-resolved fluorescence resonance energy transfer assays, respectively. This compound effectively enhances the mRNA expression of key Nrf2 target genes, including GSTM3, HMOX2, and NQO1. Keap1-Nrf2-IN-8 is instrumental in research focused on oxidative stress response and cellular defense mechanisms.

2-Trifluoromethyl-2'-methoxychalcone is a chalcone derivative that functions as a potent activator of the Nrf2 pathway. This compound promotes the expression of antioxidant proteins and plays a crucial role in cellular protection against oxidative stress. It is particularly relevant for research applications focused on diseases linked to oxidative stress and inflammation.

Keap1-Nrf2-IN-15 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, exhibiting IC50 values of 77 nM in fluorescence polarization (FP) assays and 2.5 nM in time-resolved Förster resonance energy transfer (TR-FRET) assays. This compound enhances the activation of the Nrf2 pathway, which plays a critical role in cellular defense mechanisms against oxidative stress and inflammation. Keap1-Nrf2-IN-15 is a valuable tool for research applications focused on neuroprotection, cancer therapy, and the modulation of antioxidant responses.

Keap1-Nrf2-IN-12 is a potent inhibitor of the Keap1-Nrf2 interaction, exhibiting an IC50 value of 2.30 µM. This compound effectively modulates the Nrf2 signaling pathway, which is critical for cellular defense against oxidative stress. Additionally, Keap1-Nrf2-IN-12 demonstrates metabolic stability in human liver microsomes, making it a valuable tool for research applications focused on oxidative stress response and related therapeutic targets.

Carlinoside is a flavone glycoside that exhibits hepatoprotective properties. It effectively reduces hepatic bilirubin accumulation by enhancing bilirubin-UDP-glucuronosyltransferase (UGT) activity through the activation of Nrf2 gene expression. This compound holds potential for the management of hyperbilirubinemia associated with liver dysfunction.

Keap1-Nrf2-IN-22 is a selective inhibitor of the Keap1-Nrf2 interaction, exhibiting a KD2 value of 42.2 nM for Keap1. This compound is valuable for investigating the regulatory mechanisms of oxidative stress and cytoprotection in cellular environments. Key research applications include the study of acute lung injury (ALI) and cerebral ischemia/reperfusion (I/R) injury, where modulation of the Nrf2 pathway may provide therapeutic insights.

Keap1-IN-2 is a potent KEAP1 inhibitor with an IC50 of 2 nM, designed to indirectly activate Nrf2. By inhibiting KEAP1, this compound enhances cellular antioxidant capacity and promotes the accumulation and nuclear translocation of Nrf2, preventing its degradation. Keap1-IN-2 is applicable in research exploring diseases linked to oxidative stress, including inflammatory bowel disease, Crohn's disease, and immune disorders such as ulcerative colitis.

TPNA10168 is an Nrf-2 activator that enhances the Keap1-Nrf2-ARE signaling pathway. It exhibits neuroprotective properties against oxidative stress-induced cellular damage and significantly downregulates the expression of inflammatory genes such as TNF-α, IL-1β, IL-6, and iNOS. TPNA10168 is suitable for research applications focused on anti-inflammatory responses and neurological disorders.

WN1316 is an orally active antioxidant agent that exhibits neuroprotective properties. It is primarily utilized in research focused on amyotrophic lateral sclerosis (ALS), making it a valuable tool for studying neurodegenerative diseases and the underlying mechanisms of oxidative stress in neuronal cells.

CPDT is a potent activator of the transcription factor Nrf2, which plays a crucial role in cellular defense mechanisms. It significantly induces the expression of phase 2 enzymes, including glutathione S-transferase, NAD(P)H:quinone:oxidoreductase 1, and glutamate cysteine synthetase. Research demonstrates that CPDT enhances glutathione levels in rat bladder in vivo and in cultured bladder cells in vitro, highlighting its potential applications in studies of oxidative stress and antioxidant responses.

Keap1-Nrf2-IN-17 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction. This compound enhances the activation of the Nrf2 pathway, which plays a critical role in cellular defense against oxidative stress and inflammation. Keap1-Nrf2-IN-17 is valuable for research applications focused on understanding the mechanisms of oxidative stress response and exploring therapeutic options for related diseases.

S21-1011 is a selective inhibitor of butyrylcholinesterase (BChE) with IC50 values of 0.059 μM for equine BChE and 0.162 μM for human BChE. This compound demonstrates effective blood-brain barrier permeability and favorable pharmacokinetic properties. Additionally, S21-1011 exhibits anti-inflammatory activity by activating the keap1-Nrf2-ARE signaling pathway, with an EC50 of 23.48 μM for antioxidant response element activation. Its potential to ameliorate cognitive impairments in murine models of Alzheimer’s disease makes it relevant for neurodegenerative research applications.

AChE/Nrf2 Modulator 1 is an orally active compound that targets both acetylcholinesterase (AChE) and the nuclear factor erythroid 2-related factor 2 (Nrf2). It exhibits significant Nrf2 inductive activity along with potent AChE inhibitory effects, presenting IC50 values of 0.07 μM for eel AChE and 0.38 μM for human AChE. This compound is primarily utilized in research focused on Alzheimer's disease, providing insights into neuroprotective mechanisms and cholinergic system modulation.

Ginnalin A, a potent Nrf2 activator, demonstrates significant antiproliferative activity against HCT116, SW480, and SW620 cancer cell lines, with IC50 values of 24.8, 22.0, and 39.7 μM, respectively. This compound induces S phase arrest in cancer cells and activates the p62-Keap1-Nrf2 signaling pathway, leading to the upregulation of mRNA and protein expressions of key protective markers such as Nrf2, HO-1, and NQO1. Additionally, Ginnalin A promotes the translocation of Nrf2 from the cytoplasm to the nucleus, making it a valuable tool for research into colon cancer mechanisms and potential therapies.

K67 is a selective inhibitor targeting the interaction between Keap1 and S349 phosphorylated p62, with an IC50 of 1.5 μM. This compound demonstrates a weaker inhibitory effect on the Keap1-Nrf2 interaction (IC50 of 6.2 μM) and functions by competitively binding to Keap1's binding site, disrupting the aberrant activation of the p62-dependent Nrf2 pathway. K67 has been shown to inhibit tumor cell proliferation and increase the sensitivity of hepatocellular carcinoma (HCC) cells to chemotherapeutic agents by restoring Keap1-mediated ubiquitination and subsequent degradation of Nrf2. This makes K67 a valuable tool for investigating therapeutic strategies in cancer research.

PRL-295 is an orally active inhibitor targeting the interaction between Keap1 and Nrf2. By enhancing the thermal stability of Keap1, PRL-295 disrupts its binding to Nrf2, leading to the activation of Nrf2-dependent genes such as NAD(P)H:quinone oxidoreductase 1 (NQO1). This compound has demonstrated protective effects against Acetaminophen-induced liver injury in murine models, making it a valuable tool for research into oxidative stress and related pathologies.

Hydroxycitric acid is an orally active compound that serves as a multifunctional activator of Nrf2, AMPK, and mTOR pathways. It enhances the expression of antioxidant enzymes, such as superoxide dismutase, and increases glutathione levels, thereby mitigating oxidative stress and ferroptosis, particularly in renal tubular epithelial cells. Additionally, hydroxycitric acid induces cell cycle arrest in cancer cells and promotes DNA fragmentation through modulation of the AMPK and mTORC1/S6K signaling pathways. This compound is valuable for research in oxidative stress, cancer biology, and metabolic regulation.

Hydroxycitric acid (tripotassium) is a potent activator of the Nrf2, AMPK, and mTOR signaling pathways. It enhances the expression of antioxidant enzymes, elevates glutathione levels, and inhibits ferroptosis, thereby providing protection against oxidative stress and promoting cellular health. This compound is actively engaged in regulating renal and pulmonary vascular functions and is also implicated in the induction of apoptosis in cancer cells through cell cycle arrest and DNA fragmentation. Its multi-target bioactivity makes it a valuable tool in research focused on oxidative stress, cancer biology, and metabolic regulation.

ML334 is a potent NRF2 activator that functions by inhibiting the Keap1-NRF2 protein-protein interaction. With a binding affinity to the Keap1 Kelch domain of 1 μM, ML334 effectively promotes NRF2 expression and its subsequent nuclear translocation, thereby enhancing antioxidant response element (ARE) activity. This compound is valuable for research applications focused on oxidative stress, neuroprotection, and cellular responses to environmental stimuli.

Nrf2 activator-6 is a tetrahydroisoquinoline compound that functions as an activator of the Nrf2 pathway. It exhibits an IC50 of 5 nM for inhibiting the Kelch domain-Nrf2 interaction, thereby promoting the transcriptional activation of antioxidant response elements. This compound is valuable in research applications focused on oxidative stress, inflammation, and neuroprotection.

Nrf2 activator-7 is a potent activator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. By significantly enhancing Nrf2 signaling, it promotes the expression of antioxidant and cytoprotective genes. This reagent is valuable in research focused on oxidative stress, inflammation, and cellular defense mechanisms.

Nordihydrocapsaicin is a capsacinoid analog known for its pungent properties and oral bioactivity. This compound exhibits potential anti-cancer activities and is derived from both fresh and processed peppers. It may induce a burning sensation upon consumption, making it relevant for research in pain mechanisms and anti-tumor effects.

(R,S,R)-ML334 is the isomer of ML334, serving as a valuable experimental control in research. This compound acts primarily as a cell-permeable activator of NRF2 by inhibiting the Keap1-NRF2 protein-protein interaction. With a binding affinity of 1 µM to the Kelch domain of Keap1, (R,S,R)-ML334 enhances NRF2 expression, promotes its nuclear translocation, and induces antioxidant response elements (ARE) activity, making it significant for studies related to oxidative stress and cellular defense mechanisms.

Chikusetsusaponin IVa is an orally active anti-inflammatory agent that targets YAP, demonstrating a binding affinity with a KD value of 0.388 mM. This compound effectively reduces the expression of inflammatory mediators such as IL-6, IL-10, and COX-2, while modulating nitric oxide production and promoting reactive oxygen species generation. Additionally, Chikusetsusaponin IVa induces apoptosis, inhibits MAPK and TAZ signaling pathways, and regulates Nrf2 and JAK/STAT pathways. It exhibits potential as an anti-H9N2 avian influenza virus agent and demonstrates anti-cancer properties, along with hepatoprotective and osteoprotective effects, making it a valuable tool for research in inflammation and cancer biology.